QURE News

QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE

QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Investors Have Opportunity to Lead Class Action Lawsuit!

Pomerantz LLP Informs Shareholders of Securities Class Action Against uniQure N.V. – QURE

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action – Hagens Berman

QURE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE

Holzer & Holzer, LLC Reminds Investors of April 13, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Kyndryl Holdings, Inc. (KD) and uniQure N.V. (QURE)